AMF Tjanstepension 13F: Adds $76M to Eli Lilly and (LLY) Stake
Key Points
- AMF Tjanstepension bought 65,262 additional shares of Eli Lilly and Company LLY to grow its stake to 543,339 shares valued at $628,686,690.
- Eli Lilly trades recently around $1,301.24 per share, sitting well above its 50-day and 200-day moving averages ahead of its October 29 earnings report.
- Wall Street firms including JP Morgan and Morgan Stanley maintain favorable ratings on the drug maker with price targets stretching as high as $1,600.
Get Eli Lilly and Company text alerts
We text you when insiders, Congress, analysts or big funds move on $LLY.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Eli Lilly and Company alert may contain errors. Disclosures
AMF Tjanstepension boosted its holdings in Eli Lilly and Company NYSE:LLY by 13.7% during the third quarter, purchasing an additional 65,262 shares to bring its total investment to 543,339 shares. According to a Form 13F filing filed with the Securities and Exchange Commission on October 22, 2026, the updated stake was worth approximately $628,686,690 at the close of the period.
LLY
Eli Lilly and Company
What Changed in AMF Tjanstepension's Eli Lilly Position
The pension fund lifted its position from 478,077 shares up to 543,339 shares over the course of the quarter. This 13.65% expansion of its portfolio footprint reflects steady institutional appetite for the pharmaceutical major as shares trade near historical highs.
Other Institutional Activity in Eli Lilly
Other large investors adjusted their positions in Eli Lilly around the same reporting window. Wealthcare Advisory Partners grew its holdings by 2,980 shares, ending with 13,284 shares worth about $15,370,704 following a 28.9% increase. Lilly Endowment, Inc reduced its massive holding by 307,272 shares, finishing with 90,066,78 shares valued at $117,689,614,205 after a 0.3% cut. PNC Financial Services Group, Inc. trimmed its stake by 5,133 shares to hold 51,322,720 shares worth about $67,062,881,989. Axxcess Wealth Management cut its position by 12,282 shares, leaving it with 9,539 shares valued at $11,038,261 after a 56.3% reduction.
Eli Lilly and Company Stock Up 1.4%
Eli Lilly shares recently traded around $1,301.24, sitting 9.9% above their 50-day moving average and 20.2% above their 200-day moving average. The stock sits just 0.8% below its 52-week high of $1,311.75 and far above its 52-week low of $806.02.
Recent Earnings
The drug manufacturer reported trailing twelve month revenue of $79,660,039,680 alongside basic earnings of $29.79 per share. The company operates with a net profit margin of 33.5% and a return on equity of 102.3%, with its next quarterly earnings release scheduled for October 29, 2026.
Dividend
Eli Lilly distributes an annual dividend rate of $6.92 per share, translating to a dividend yield of 0.54% based on a payout ratio of 21.7%.
Insider Buying and Selling at Eli Lilly and Company
Company insiders executed several transactions prior to the filing. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at an average price of $1,190.00 for a total value of $5,950,000. Officer Donald A Zakrowski sold 2,000 shares on August 10, 2026, at $1,185.01 per share totaling $2,370,020. Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, at $1,175.10 per share for a total value of $7,638,150.
Analysts Set New Price Targets
Wall Street analysts remain broadly optimistic about the pharmaceutical giant. On September 28, 2026, JP Morgan maintained its Overweight rating and raised its price target from $1400.00 to $1500.00. Morgan Stanley maintained an Overweight rating on October 7, 2026, lifting its target from $1419.00 to $1430.00. Cantor Fitzgerald maintained an Overweight rating on October 8, 2026, moving its target from $1410.00 to $1440.00. RBC Capital reiterated an Outperform rating with a $1500.00 target on October 12, 2026. Leerink Partners maintained an Outperform rating on October 21, 2026, nudging its target from $1309.00 to $1316.00. The stock carries a consensus buy recommendation from 30 analysts, with a mean price target of $1,331.55.
About Eli Lilly and Company
Eli Lilly and Company is a major healthcare enterprise based in Indianapolis, Indiana, focusing on the discovery, development, and marketing of pharmaceutical products for humans. The company supplies vital treatments across endocrinology, oncology, and immunology worldwide.
Bottom Line
AMF Tjanstepension's expanded stake comes as Eli Lilly prepares to report its latest financial results on October 29, 2026. Observers will monitor whether ongoing demand for its flagship therapies sustains its premium valuation and meets elevated analyst expectations.
Related Filing Alerts
Source: AMF Tjanstepension's 13F filing on $LLY (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts